TD Cowen Downgrades Terns Pharma to Hold, Announces $53 Price Target

Benzinga Newsdesk www.benzinga.com Negative 90.2%

Neg 90.2% Neu 0% Pos 0%

TD Cowen analyst Ritu Baral downgrades Terns Pharma (NASDAQ:TERN) from Buy to Hold and announces $53 price target.

Comments

No comments yet. Be the first!